For all investor queries, please contact info@vasomune.com.
Latest News
Vasomune Announces FDA Allowance of IND Application for AV-001 for the Treatment of Hospitalized Patients with COVID-19
TORONTO, Ontario – (Business Wire) – November 12, 2020 – Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the U.S. Food and Drug Administration
November 12, 2020
No Comments
Learn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing
Vasomune Therapeutics has been working with University of Iowa Pharmaceuticals (UIP) through a strategic partnership toward the manufacture of AV-001, a biopharmaceutical therapeutic that treats
August 18, 2020
No Comments
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause,
August 18, 2020
No Comments
Vasomune Therapeutics Announces Clinical and Scientific Advisory Board
Vasomune Therapeutics Announces Clinical and Scientific Advisory Board Esteemed Leaders in Translation, Therapeutic Development and Critical Care Medicine TORONTO, Ontario – (Business Wire) – May
May 12, 2020
No Comments